(Reuters) - But the company could not say what impact the decision would have on its European sales of Visudyne, which is used in the treatment of age-related macular degeneration.
QLT reported a 60-percent drop in its first-quarter earnings due to a sharp decline in sales of Visudyne in the United States and Europe.
Read more at Reuters.com Market News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment